Biologic treatments for RA carry similar infection risk

Biologic treatments for RA carry similar infection risk
The risk of hospitalized bacterial infections in older rheumatoid arthritis patients is similar for rituximab or abatacept compared to etanercept, although it is higher for infliximab, according to a study published in the July issue of Arthritis Care & Research.

(HealthDay)—The risk of hospitalized bacterial infections in older rheumatoid arthritis (RA) patients is similar for rituximab or abatacept compared to etanercept, although it is higher for infliximab, according to a study published in the July issue of Arthritis Care & Research.

Jeffrey R. Curtis, M.D., from the University of Alabama at Birmingham, and colleagues utilized 1998 to 2011 data from the U.S. Veterans Health Administration to identify RA patients initiating , abatacept, or anti-tumor necrosis factor (anti-TNF) therapy. The authors sought to assess the comparative risk of hospitalized infection associated with anti-TNF and non-anti-TNF biologic agents.

The researchers found that 3,152 unique RA patients (mean age, 60 years; 87 percent male) had 4,158 biologic treatment episodes of rituximab (596 initiations), abatacept (451 initiations), and anti-TNF agents (3,111 initiations). For rituximab, the hospitalized infection rate was 4.4 per 100 person-years; rates were 2.8 for abatacept and 3.0 for anti-TNF. The adjusted rates of hospitalized infection were similar for adalimumab (hazard ratio [HR], 1.4; 95 percent confidence interval [CI], 0.9 to 2.2), abatacept (HR, 1.1; 95 percent CI, 0.6 to 2.1), or rituximab (HR, 1.4; 95 percent CI, 0.8 to 2.6), compared to etanercept, although it was increased for (HR, 2.3; 95 percent CI,, 1.3 to 4.0).

"In older, predominantly male U.S. veterans with RA, the risk of hospitalized bacterial infections associated with rituximab or abatacept was similar to etanercept," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Three weeks since last Ebola case in Mali: WHO

2 hours ago

Mali has not had a case of Ebola for three weeks, the World Health Organization said Wednesday, completing one of the two incubation periods the country needs to be declared free of the virus.

Migraine may double risk for facial paralysis

3 hours ago

Migraine headache may double the risk of a nervous system condition that causes facial paralysis, called Bell's palsy, according to a new study published in the December 17, 2014, online issue of Neurology, the medical journa ...

Anti-diabetic drug springs new hope for tuberculosis patients

10 hours ago

A more effective treatment for tuberculosis (TB) could soon be available as scientists have discovered that Metformin (MET), a drug for treating diabetes, can also be used to boost the efficacy of TB medication without inducing ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.